Global Antibody Drug Conjugates Drug Market Size, Projections, Segmentation, Challenges, Opportunities, Trends and Forecast by 2023
OrbisResearch.com has published new research report on “Global Antibody Drug Conjugates Drug Sales, Pipeline Analysis (By Phase, Linker, Technology, and Indication) and Global Market Forecasts to 2023” to its database.
Dallas, United States – March 12, 2018 /MarketersMedia/ —
Antibody Drug Conjugates are the fastest growing class of oncology therapeutics. These are monoclonal antibody based therapies which have achieved great success in the field of cancer treatment, primarily when used with cytotoxic drugs. ADC is a class of therapeutics which harnesses the antigen-selectivity of monoclonal antibodies to deliver the highly potent cytotoxic drugs to antigen expressing tumor cells. The use of monoclonal antibody directed delivery confers a therapeutic index to highly potent cytotoxic drugs, increasing both the efficacy and safety of therapy. Such novel anti-cancer drugs are being used these days to target cancers, while minimizing the exposure of healthy tissue. The recent approval of four ADCs in the global market and a strong pipeline of such drugs, highlight the potential for new therapeutic innovations in this industry.
According to the RNCOS report entitled “Global Antibody Drug Conjugates Drug Sales, Pipeline Analysis (By Phase, Linker, Technology, and Indication) & Global Market Forecasts to 2023”, the Global Antibody Drug Conjugates Market is anticipated to witness a double digit growth during 2017-2023. The report provides information about the current and future market scenario of the Global ADCs Market. The report also highlights the major drivers, such as increasing incidences of cancer and advances in linking technologies, for the Global Antibody Drug Conjugates Market. Furthermore, the report also gives information related to the commercially available ADCs such as ADCETRIS, Kadcyla, Mylotarg and Besponsa.
Moreover, few hindrances, such as high cost of production cost, lack of experienced manufacturers and regulatory challenges, which are slowing down the growth of the Global ADCs Market, have also been mentioned in the report. In addition, the report also highlights various trends and developments taking place in this market.
Request a Free Sample of The Report: http://orbisresearch.com/contacts/request-sample/2085096
Furthermore, in this report, we have structured the information regarding ADCs at various stages of clinical development that are under research or in collaboration, and those individually being developed by companies. The pipeline chapter provides in depth analysis of ADCs of companies as well as research organizations by clinical phase, indications for which they are being developed, type of linker, drugs, and technology. Additionally, the study provides all-inclusive current analysis of various ADCs in advanced as well as early stages of development. Moreover, our report places an emphasis on the strategic alliances that can impact industry’s growth.
The prominent players in Global Antibody Drug Conjugates Market have been discussed in the last section of the report. A brief business overview and financial information about each of these players has been provided, along with their product portfolios, product pipeline and recent developments. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the Global Antibody Drug Conjugates Market.
Buy The Report@http://orbisresearch.com/contact/purchase/2085096
Major Points From The Table Of Contents:
Analyst View
Research Methodology
Antibody Drug Conjugate (ADC) – An Introduction
Global Antibody Drug Conjugates Market Outlook to 2023
Commercialized Antibody Drug Conjugates
Antibody Drug Conjugates Pipeline Analysis
Drivers and Challenges
Major Potential Antibody Drug Conjugates in Pipeline
Trends and Developments
Strategic Alliances in the Global Antibody Drug Conjugates Industry
Competitive Assessment
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Information:
Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +9164101019
Email: sales@orbisresearch.com
Contact Info:
Name: Hector Costello
Email: sales@orbisresearch.com
Organization: Orbis Research
Address: 4144N Central Expressway, Suite 600, Dallas, Texas – 75204, U.S.A.
Phone: +1 (214) 884-6817
For more information, please visit http://orbisresearch.com/reports/index/-global-antibody-drug-conjugates-drug-sales-pipeline-analysis-by-phase-linker-technology-and-indication-and-global-market-forecasts-to-2023
Source: MarketersMedia
Release ID: 312120
Copyright © 1999-2013 SproutNews.com
